Gastric Cancer:单纯手术是否足以治疗具有广泛淋巴结转移的T1型胃癌

2019-10-06 不详 MedSci原创

单独手术治疗是否足以治疗病理分期T1N2M0(IIA期),T1N3a / bM0(IIB / IIIB期)和T3N0M0(IIA期)胃癌的患者目前仍不清楚。本项研究旨在探究二者之间的关系。

背景

单独手术治疗是否足以治疗病理分期T1N2M0(IIA期),T1N3a / bM0(IIB / IIIB期)和T3N0M0(IIA期)癌的患者目前仍不清楚。本项研究旨在探究二者之间的关系。


方法

研究人员回顾性分析了2000年1月至2012年12月在日本国立癌症中心医院诊断为pT1N2-3b/pT3N0癌并接受R0胃切除术并淋巴结清扫术的236例患者的临床记录,并对其做了相关统计分析。


结果

病理诊断为T1N2-3b和T3N0癌症患者的5年无复发生存率(RFS)(95%置信区间[CI])为73.9%(63.1-84.7)和89.5%(84.0-95.0) )。经多因素Cox回归分析确定的T1N2-3癌症患者生存的唯一重要预后因素是pN分期(N3a / N2:危险比[HR] 2.940,95%CI 1.314–5.577; N3b / N2:HR 8.688、95%CI 3.096–24.382)和肿瘤直径(<30 /≥30 mm)(HR 2.919; 95%CI 1.351–6.304)。我们使用这两个重要的预后因素将pT1N2-3胃癌患者分为3个风险类别(高,中,低),发现3个风险组之间的5年RFS发生率显着不同(低风险,93.0% ;中度风险为66.7%;高风险为25.0%;P<0.001)。


结论

直径≥30 mm的pT3N0和pT1N2的预后良好,而肿瘤直径<30 mm的pT1N2-3的预后相对较差。


原始出处:

Masahiro Yura. Et al. Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases?. Gastric Cancer. 2019.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072728, encodeId=1f3120e272822, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Apr 25 07:03:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893646, encodeId=c80c18936461e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Dec 09 11:03:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712127, encodeId=0b551e12127f9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 12 13:03:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293076, encodeId=8e1412930e65e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302522, encodeId=88eb1302522b8, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
    2020-04-25 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072728, encodeId=1f3120e272822, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Apr 25 07:03:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893646, encodeId=c80c18936461e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Dec 09 11:03:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712127, encodeId=0b551e12127f9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 12 13:03:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293076, encodeId=8e1412930e65e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302522, encodeId=88eb1302522b8, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
    2019-12-09 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072728, encodeId=1f3120e272822, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Apr 25 07:03:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893646, encodeId=c80c18936461e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Dec 09 11:03:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712127, encodeId=0b551e12127f9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 12 13:03:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293076, encodeId=8e1412930e65e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302522, encodeId=88eb1302522b8, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072728, encodeId=1f3120e272822, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Apr 25 07:03:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893646, encodeId=c80c18936461e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Dec 09 11:03:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712127, encodeId=0b551e12127f9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 12 13:03:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293076, encodeId=8e1412930e65e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302522, encodeId=88eb1302522b8, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
    2019-10-08 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2072728, encodeId=1f3120e272822, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Apr 25 07:03:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893646, encodeId=c80c18936461e, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Mon Dec 09 11:03:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712127, encodeId=0b551e12127f9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue May 12 13:03:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293076, encodeId=8e1412930e65e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302522, encodeId=88eb1302522b8, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 08 04:03:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

相关资讯

Gastric Cancer:血清ANOS1水平可作为胃癌的诊断生物标志物

发现特异性的血清生物标志物可能会改善胃癌患者(GC)的治疗效果。有研究已经确定了候选血清标志物,anosmin 1(ANOS1),二氢嘧啶酶样3(DPYSL3)和黑色素瘤相关抗原D2(MAGE-D2),并通过单中心回顾性分析评估了它们的临床意义。在这里,研究人员进行了一项前瞻性多中心观察研究,旨在验证这些潜在标志物的诊断性能。

J Gastroenterology:PD-L1表达在原发性胃和肠弥漫性大B细胞淋巴瘤中的预后影响

弥漫性大B细胞淋巴瘤(DLBCL)是一种异质性疾病,也是最常见的胃肠道淋巴瘤。胃肠DLBCL(giDLBCL)患者的预后/预测指标到底是什么存在很多争议。研究人员在本项研究中探究了程序性细胞死亡配体1(PD-L1)的表达与giDLBCL的预后关系。

Gastric Cancer: 低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险

静脉血栓栓塞(VTE)与晚期胃癌(AGC)高度相关,有时是致命的。VTE的预测因子尚未确定,直接口服抗凝剂(DOAC)对AGC相关VTE的疗效和安全性仍有待澄清。因此,本项研究旨在探究二者之间的关系。

JAMA Surg: 手术联合术中腹腔灌洗与单独手术治疗局部晚期胃癌的效果比较

腹膜转移是胃癌患者术后复发的最常见模式。术中腹腔灌洗(EIPL)是治疗局部晚期胃癌腹膜转移的新型预防策略; 然而,EIPL的安全性和有效性目前尚不清楚。因此,本项研究旨在评估接受手术联合EIPL或单纯手术治疗的晚期胃癌的效果差异。

J Gastroenterology:新型尿microRNA可以作为检测胃癌的新型生物标志物

胃癌(GC)是全球癌症死亡的最常见原因之一; 然而,目前还没有可靠的和非侵入性的GC筛查方法。因此,本项研究旨在开发一种由尿微小RNA(miRNA)组成的用于GC检测的生物标志物。

BMJ: 胃排空速度加快能够改善肥胖患者抽吸治疗的效果

吸入治疗(AT)对肥胖的有效性依赖于餐后的最佳抽吸时间,其可以根据患者的胃排空速率(GE)而变化。本项研究的目的是确定基线GE率是否与吸入效率(AE)的差异相关。